Survival Impact of Optimal Surgical Cytoreduction in Recurrent Epithelial Ovarian Cancer with Brain Metastasis

被引:10
|
作者
Keskin, Serkan [1 ]
Kucucuk, Seden [2 ]
Ak, Naziye [3 ]
Atalar, Banu [4 ]
Sari, Murat [3 ]
Sozen, Hamdullah [5 ]
Ibis, Kamuran [2 ]
Topuz, Samet [5 ]
Saip, Pinar [3 ]
机构
[1] Istanbul Univ, Dept Med Oncol, Mem Sisli Hosp, Istanbul, Turkey
[2] Istanbul Univ, Dept Radiat Oncol, Inst Oncol, Istanbul, Turkey
[3] Istanbul Univ, Dept Med Oncol, Inst Oncol, Istanbul, Turkey
[4] Acibadem Univ, Dept Radiat Oncol, Istanbul, Turkey
[5] Istanbul Univ, Dept Gynecol Oncol, Istanbul Fac Med, Istanbul, Turkey
关键词
Ovarian carcinoma; Brain metastasis; Survival; Prognostic factors; CENTRAL-NERVOUS-SYSTEM; PROGNOSTIC-FACTORS; CARCINOMA; MANAGEMENT;
D O I
10.1159/000494334
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Aim: The aim of this study was to determine the clinicopathological characteristics, treatment details and outcome of patients with brain metastasis from epithelial ovarian carcinoma (EOC). Methods: This study included 21 patients diagnosed with brain metastasis from EOC between 1999 and 2009. Results: Median age was 61 years (range 38-77). The median time elapsed from EOC diagnosis to brain metastasis detection was 32 months. Single brain metastases were found in 10 (48%) cases, and there was extracranial disease in 11 (52%) cases. During the mean 86 months of follow-up, 18 of the patients (86%) died of the disease and 3 (14%) were alive with disease. The median survival time after the initial diagnosis of brain metastasis was 9 months. The median overall survival (OS) from initial diagnosis of EOC was 50 months. In univariate analysis, prolonged time from initial diagnosis to central nervous system metastasis (more than 32 months) (p = 0.001), treatment with radiotherapy (p < 0.001), optimal cytoreductive operation (p = 0.02) were all positively correlated with OS. Conclusion: The prognosis of patients with brain metastasis from EOC is still poor. The significant predictors of survival in our series were whole brain radiotherapy, prolonged elapsed time from initial diagnosis to brain metastasis and optimal cytoreductive surgery. (c) 2019 S. Karger AG, Basel
引用
收藏
页码:101 / 105
页数:5
相关论文
共 50 条
  • [1] Surgical cytoreduction for recurrent epithelial ovarian cancer
    Al Rawahi, Thuria
    Lopes, Alberto D.
    Bristow, Robert E.
    Bryant, Andrew
    Elattar, Ahmed
    Chattopadhyay, Supratik
    Galaal, Khadra
    [J]. COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2013, (02):
  • [2] Survival impact of surgical cytoreduction in stage IV epithelial ovarian cancer
    Bristow, RE
    Montz, FJ
    Lagasse, LD
    Leuchter, RS
    Karlan, BY
    [J]. GYNECOLOGIC ONCOLOGY, 1999, 72 (03) : 278 - 287
  • [3] SURGICAL SECONDARY CYTOREDUCTION IN RECURRENT OVARIAN CANCER PATIENTS WITH LIVER METASTASIS
    Conte, C.
    Gallotta, V.
    d'Indinosante, M.
    Capoluongo, E.
    Minucci, A.
    De Rose, A.
    Ardito, F.
    Giuliante, F.
    Di Giorgio, A.
    Zannoni, G. F.
    Margreiter, C.
    Fagotti, A.
    Scambia, G.
    Ferandina, G.
    [J]. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2019, 29 : A134 - A134
  • [4] Does sites of recurrence impact survival in secondary cytoreduction surgery for recurrent epithelial ovarian cancer?
    Kumar, Satyam
    Srinivasan, Ananth
    Phillips, Andrew
    Madhupriya, R.
    Pascoe, Jennifer
    Nevin, James
    Elattar, Ahmed
    Balega, Janos
    Cummins, Carole
    Sundar, Sudha
    Kehoe, Sean T.
    Singh, Kavita
    [J]. JOURNAL OF OBSTETRICS AND GYNAECOLOGY, 2020, 40 (06) : 849 - 855
  • [5] Clinical Outcome of Tertiary Surgical Cytoreduction in Patients with Recurrent Epithelial Ovarian Cancer
    Christina Fotopoulou
    Rolf Richter
    Ioana Elena Braicu
    Sven-Christian Schmidt
    Peter Neuhaus
    Werner Lichtenegger
    Jalid Sehouli
    [J]. Annals of Surgical Oncology, 2011, 18 : 49 - 57
  • [6] CLINICAL OUTCOME OF TERTIARY SURGICAL CYTOREDUCTION IN PATIENTS WITH RECURRENT EPITHELIAL OVARIAN CANCER
    Arvas, M. M.
    Bese, T. T.
    Demirkiran, F.
    Sal, V.
    Tokgozoglu, N.
    Sofiyeva, N.
    Sanioglu, C.
    [J]. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2014, 24 (09) : 315 - 315
  • [7] Secondary Surgical Cytoreduction for Recurrent Ovarian Cancer
    Coleman, Robert L.
    Spirtos, Nick M.
    Enserro, Danielle
    Herzog, Thomas J.
    Sabbatini, Paul
    Armstrong, Deborah K.
    Kim, Jae-Weon
    Park, Sang-Yoon
    Kim, Byoung-Gie
    Nam, Joo-Hyun
    Fujiwara, Keiichi
    Walker, Joan L.
    Casey, Ann C.
    Alvarez Secord, Angeles
    Rubin, Steve
    Chan, John K.
    DiSilvestro, Paul
    Davidson, Susan A.
    Cohn, David E.
    Tewari, Krishnansu S.
    Basen-Engquist, Karen
    Huang, Helen Q.
    Brady, Mark F.
    Mannel, Robert S.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2019, 381 (20): : 1929 - 1939
  • [8] Clinical Outcome of Tertiary Surgical Cytoreduction in Patients with Recurrent Epithelial Ovarian Cancer
    Fotopoulou, Christina
    Richter, Rolf
    Braicu, Ioana Elena
    Schmidt, Sven-Christian
    Neuhaus, Peter
    Lichtenegger, Werner
    Sehouli, Jalid
    [J]. ANNALS OF SURGICAL ONCOLOGY, 2011, 18 (01) : 49 - 57
  • [9] Secondary Surgical Cytoreduction for Recurrent Ovarian Cancer
    Coleman, Robert L.
    Spirtos, Nick M.
    Enserro, Danielle
    Herzog, Thomas J.
    Sabbatini, Paul
    Armstrong, Deborah K.
    Kim, Jae-Weon
    Park, Sang-Yoon
    Kim, Byoung-Gie
    Nam, Joo-Hyun
    Fujiwara, Keiichi
    Walker, Joan L.
    Casey, Ann C.
    Secord, Angeles Alvarez
    Rubin, Steve
    Chan, John K.
    DiSilvestro, Paul
    Davidson, Susan A.
    Cohn, David E.
    Tewari, Krishnansu S.
    Basen-Engquist, Karen
    Huang, Helen Q.
    Brady, Mark F.
    Mannel, Robert S.
    [J]. OBSTETRICAL & GYNECOLOGICAL SURVEY, 2020, 75 (03) : 165 - 166
  • [10] Secondary Surgical Cytoreduction for Recurrent Ovarian Cancer
    Paulino, Eduardo
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (07): : 685 - 686